PSCC's institutional partners
The PSCC is at the heart of a first-in-class ecosystem that brings together academic and industrial experts from a wide range of disciplines, technologies, organizations and institutions.
The PSCC acts as a catalyst for transforming potentially revolutionary approaches into industrial diagnostic and therapeutic solutions for the fight against cancer.
The cluster is formalizing some of its partnerships, in particular with players who, like the PSCC, have a cross-functional mission to support companies and projects. These partnerships are set to expand, for the benefit of innovation and patients alike.
EIT Health is a European network of healthcare investors supported by the European Union. Our partnership with EIT Health provides PSCC projects with privileged access to European investors, as well as training and support.
Medicen is the healthcare competitiveness cluster in the Île-de-France region. Our partnership is embodied in particular by joint membership in Medicen and PSCC Connect. Together, the PSCC and Medicen contribute to the ecosystem and exchange expertise for the benefit of projects, for example, regarding access to non-dilutive financing.
ITCC is a European academic network of experts in pediatric oncology. The objective of the partnership with the PSCC is to encourage and support the development of solutions targeting pediatric cancers. To support innovation, ITCC offers expertise (design of pediatric development plans, preparation of clinical trials, etc.) and, via ITCC P4, a preclinical proof-of-concept platform in pediatric oncology (PDX models). ITCC is leading the PSCC Pediatrics working group alongside Sanofi.
Matwin, a subsidiary of Unicancer, is a national player that aims to develop entrepreneurship in oncology through partnering events, including Meet2Win, and a project acceleration program, submitted to an international board composed of industrial decision-makers in oncology and academic opinion leaders in the sector. The PSCC enriches Matwin's offering by providing projects selected in its program with part of its support offer. In addition, they work together to drive the OncoStart training program.
OncoSTART is a collective that encourages and energizes French entrepreneurship in the fight against cancer. OncoSTART's members are the cancer research centers, the Carnot Institutes, Gustave Roussy Transfert, Matwin, Unicancer, LSLead, and, since 2022, the PSCC. Together, these stakeholders implement initiatives to promote entrepreneurship, including awareness days, training sessions, and events.
Awarded the Carnot label in 2020, the OPALE Carnot Institute is a preferred partner of healthcare manufacturers for the research and development of innovative solutions for the diagnosis, treatment, and monitoring of patients suffering from leukemia and related diseases, together the most deadly blood cancer and the leading childhood cancer. With approximately 500 researchers, clinicians, and operational staff spread across 27 entities led by scientific opinion leaders and supported by leading regulatory authorities (INSERM, CNRS, CEA, EFS, AP-HP, Université Paris-Cité, etc.), OPALE offers manufacturers unique access to the expertise and resources of a consortium with no international equivalent in the field.
CALYM is a consortium of twenty entities specializing in lymphoid disease research that offer a comprehensive range of support in the clinical research and development of therapeutic solutions, within a rapidly expanding global pharmaceutical and biotechnology market. In response to the strategic evolution of the sector, which increasingly requires biological, clinical, and technological expertise from academia, CALYM stands out through its unique positioning. Its expertise covers the entire R&D value chain, from the identification of new cellular targets to international phase III clinical trials and beyond.